Literature DB >> 16118333

Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?

S M Baumgartner-Parzer1, R Lang, L Wagner, G Heinze, B Niederle, K Kaserer, W Waldhäusl, H Vierhapper.   

Abstract

CONTEXT: Single-nucleotide polymorphisms (SNPs) of the RET protooncogene (RET) could modify disease susceptibility and clinical phenotype in patients with sporadic or familial medullary thyroid carcinoma (FMTC). OBJECTIVE/DESIGN OF THE STUDY: Because frequencies of RET SNPs have not yet been evaluated in patients with elevated serum concentrations of calcitonin (hCt), a biochemical marker for medullary thyroid carcinoma (MTC), we studied RET SNPs in patients with FMTC (n = 22), patients with sporadic MTC (n = 45), and 71 subjects presenting with moderately elevated hCt concentrations (basal, >10 pg/ml; pentagastrin stimulated, > 50 < 100 pg/ml) in comparison with an age- and gender-matched control group (n = 79) with basal hCt concentrations in the normal range (<5 pg/ml).
METHODS: After DNA extraction from citrated whole blood, RET exons 10, 11, 13, 14, 15, and 16 and exon/intron boundaries were analyzed by PCR-based cycle sequencing for RET germ line mutations, exonic (G691S, L769L, S836S, S904S) and intronic (IVS13+158; NCBI rs2472737 = IVS14-24) SNPs.
RESULTS: In FMTC patients, the F791Y mutation was found to be associated (P = 0.001) with the L769L SNP. The exonic SNPs (G691S, L769L, S836S, and S904S) were not different among the four groups. The intron 14 SNP (IVS14-24), however, was more frequent in individuals with elevated hCt serum concentrations (P = 0.016) and patients with sporadic MTC (P < 0.001) when compared with the control group.
CONCLUSIONS: These data suggest that the exon 13 (L769L) and the intron 14 (IVS14-24) SNPs could act as genetic modifiers in the development of some forms of hereditary and sporadic MTC, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118333     DOI: 10.1210/jc.2005-1278

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

2.  Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.

Authors:  X-P Qi; R-B Ying; J-M Ma; W-T Liu; Z-F Du; J Fei; C-P Yang; Q-Z Song; H-Y Jin; Z-G Chen; J-S Han; J-Q Wang; X-L Chen; Y Zhao; J-J Lu; X-N Zhang
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

3.  Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.

Authors:  A Gursoy; M F Erdogan; G Erdogan
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

4.  RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.

Authors:  Rebecca L Margraf; Rong Mao; W Edward Highsmith; Leonard M Holtegaard; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

5.  RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.

Authors:  A K Siraj; M Al-Rasheed; M Ibrahim; K Siddiqui; F Al-Dayel; O Al-Sanea; S Uddin; K Al-Kuraya
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

6.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

Review 7.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 8.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

9.  A complex endocrine conundrum.

Authors:  G Bano; V Siedel; N Beharry; P Wilson; T Cranston; S Hodgson
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

10.  Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation.

Authors:  Jian Yu Xu; Elizabeth G Grubbs; Steven G Waguespack; Camilo Jimenez; Robert F Gagel; Julie A Sosa; Rena V Sellin; Ramona Dadu; Mimi I Hu; Chardria S Trotter; Michelle Jackson; Thereasa A Rich; Samuel M Hyde; Steven I Sherman; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.